Seeyond trimmed its holdings in Baxter International Inc (NYSE:BAX) by 18.0% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 9,492 shares of the medical instruments supplier’s stock after selling 2,077 shares during the quarter. Seeyond’s holdings in Baxter International were worth $777,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in BAX. Caisse DE Depot ET Placement DU Quebec lifted its holdings in shares of Baxter International by 43.4% in the 2nd quarter. Caisse DE Depot ET Placement DU Quebec now owns 6,430,469 shares of the medical instruments supplier’s stock worth $526,655,000 after acquiring an additional 1,945,800 shares during the last quarter. Lazard Asset Management LLC raised its holdings in Baxter International by 42.7% during the 1st quarter. Lazard Asset Management LLC now owns 5,222,634 shares of the medical instruments supplier’s stock valued at $424,651,000 after buying an additional 1,562,529 shares during the last quarter. Mawer Investment Management Ltd. raised its holdings in Baxter International by 114.0% during the 1st quarter. Mawer Investment Management Ltd. now owns 2,622,591 shares of the medical instruments supplier’s stock valued at $213,243,000 after buying an additional 1,396,850 shares during the last quarter. BlackRock Inc. raised its holdings in Baxter International by 3.2% during the 1st quarter. BlackRock Inc. now owns 40,028,474 shares of the medical instruments supplier’s stock valued at $3,254,714,000 after buying an additional 1,259,763 shares during the last quarter. Finally, FIL Ltd raised its holdings in Baxter International by 64.5% during the 1st quarter. FIL Ltd now owns 2,056,928 shares of the medical instruments supplier’s stock valued at $167,248,000 after buying an additional 806,368 shares during the last quarter. Hedge funds and other institutional investors own 83.42% of the company’s stock.

A number of equities research analysts recently commented on BAX shares. Royal Bank of Canada set a $87.00 price target on shares of Baxter International and gave the company a “hold” rating in a report on Friday, July 26th. BMO Capital Markets upped their price target on shares of Baxter International to $95.00 and gave the company an “outperform” rating in a report on Friday, July 26th. Wells Fargo & Co set a $95.00 price target on shares of Baxter International and gave the company a “buy” rating in a report on Friday, July 26th. Piper Jaffray Companies reiterated a “buy” rating on shares of Baxter International in a report on Tuesday. Finally, KeyCorp started coverage on shares of Baxter International in a report on Tuesday, June 25th. They set a “sector weight” rating for the company. Four research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $85.27.

Baxter International stock traded down $0.35 during mid-day trading on Friday, reaching $87.47. 667,159 shares of the company traded hands, compared to its average volume of 2,060,176. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.78 and a quick ratio of 2.10. The firm’s 50 day moving average price is $86.31 and its 200 day moving average price is $80.10. The firm has a market capitalization of $44.71 billion, a price-to-earnings ratio of 28.68, a P/E/G ratio of 1.99 and a beta of 1.00. Baxter International Inc has a 52-week low of $61.05 and a 52-week high of $89.93.

Baxter International (NYSE:BAX) last issued its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $0.89 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.81 by $0.08. The business had revenue of $2.84 billion for the quarter, compared to the consensus estimate of $2.80 billion. Baxter International had a net margin of 14.28% and a return on equity of 21.21%. The company’s quarterly revenue was down .1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.77 EPS. On average, sell-side analysts anticipate that Baxter International Inc will post 3.37 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 1st. Stockholders of record on Friday, August 30th will be given a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 1.01%. The ex-dividend date of this dividend is Thursday, August 29th. Baxter International’s dividend payout ratio is presently 28.85%.

In other news, Director James R. Gavin III sold 7,950 shares of the company’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $87.63, for a total value of $696,658.50. Following the sale, the director now directly owns 40,932 shares of the company’s stock, valued at approximately $3,586,871.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Jacqueline Kunzler sold 5,934 shares of the company’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $88.12, for a total transaction of $522,904.08. Following the completion of the sale, the senior vice president now directly owns 3,089 shares in the company, valued at $272,202.68. The disclosure for this sale can be found here. Insiders sold a total of 14,477 shares of company stock worth $1,267,275 over the last ninety days. Insiders own 0.70% of the company’s stock.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Featured Story: Resistance Level

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.